ClinicalTrials.gg
Status unknownNCT04882826Updated May 12, 2021

Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting Conditions

A Phase 1 interventional study of Sildenafil film-coated tablet 100 mg and Viagra® film-coated tablet 100 mg in Bioequivalence, sponsored by Pharmtechnology LLC. Status unknown at 1 site in Russian Federation. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-12.

Sponsored by Pharmtechnology LLC · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified May 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This is an open-labeled (laboratory blinded), randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Viagra®, 100 mg film-coated tablets) or the test (Sildenafil, 100 mg film-coated tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent

02

Conditions studied

  • Bioequivalence

Keywords

  • Sildenafil
  • Bioequivalence
  • Viagra
03

In context

Lead sponsor

Pharmtechnology LLC is the lead sponsor of 27 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy caucasian men aged between 18 to 45 years
  2. The written consent of the volunteer to be included in the study
  3. Verified diagnosis "healthy" according to the anamnesis data and the results of standard clinical, laboratory and instrumental examination methods, physical examination and anamnestic examination
  4. 18.5-30 kg/m² according to Quetelet's weight-height index
  5. The results of an X-ray or fluorographic examination of the chest organs within the normal range (the results of an examination carried out within 12 months before the start of the study may be provided)
  6. Absence of ophthalmological disease according to the data of the ophthalmological examination
  7. Consent to use a double barrier method of (condom + spermicide) or sexual continence, as well as consent not to take part in sperm donation from the moment of taking the drug in the first period, during the entire study and within 14 days after taking the drug in the second period research
  8. Subjects are able to understand the requirements of the study, to sign a written , and also to accept all the restrictions imposed during the course of the study, and to agree to return for the required investigations

Exclusion criteria

Exclusion Criteria:

  1. Burdened allergic history, to sildenafil or that are part of any of the drugs, or intolerance to these components.
  2. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
  3. Anatomical deformation of penis (angulation, cavernous fibrosis, or Peyronie's disease).
  4. History of priapism.
  5. Hereditary retinitis pigmentosa.
  6. Episodes of development of anterior non-arteritis ischemic neuropathy of the optic nerve.
  7. Organic brain damage, a history of increased convulsive readiness.
  8. Acute or chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, and also diseases of the gastrointestinal tract, liver, kidneys and blood, eye disease.
  9. Other diseases that, in the opinion of the researcher, may affect the absorption, distribution, metabolism or excretion of both drugs, or increase the risk of negative consequences for the volunteer.
  10. The presence of mental disorders, including a history.
  11. Surgical interventions on the gastrointestinal tract, with the exception of appendectomy.
  12. Acute infectious diseases that ended less than 4 weeks before taking the drug in the first period.
  13. Dehydration due to diarrhea, vomiting or other reason within the last 24 hours before taking the drug in the first period of the study, if vomiting or diarrhea wasn't a manifestation of an infectious disease.
  14. abnormalities on the , the level of systolic blood pressure (SBP) measured in the sitting position at the time of screening \<100 mm Hg or ≥ 130 mm Hg and / or diastolic blood pressure (DBP) \<60 mm Hg or ≥ 85 mm Hg.
  15. Heart rate less than 60 beats/min or more than 90 beats/min at the time of screening, respiratory rate less than 14 or more than 18 per minute at the time of screening, body temperature below 36.0 ° C or above 37.0 °C at the time of screening.
  16. Use of any prescription and OTC drugs including herbs and food additives, vitamins that can have a significant effect on the PK of sildenafil or data on the effect of which on the pharmacokinetics of sildenafil are unknown, as well as question the characterization of the volunteer as healthy, less than 14 days before taking the drug in the first period;
  17. Use of well-known inhibitors or inducers of liver microsomal enzymes (barbiturates, omeprazole, cimetidine, etc.) or antiviral drugs less than 2 months before enrollment in the study.
  18. The use of donors of nitric oxide, organic nitrates or nitrites in any form less than 30 days before taking of the drug in the first period.
  19. Donation of plasma or blood (450 ml or more) less than 2 months (60 days) before taking the drug in the first period.
  20. Consumption of caffeine and xanthine-containing drinks and products (tea, coffee, chocolate, cola, etc.), products containing poppy seeds, less than 48 hours before taking the drug in the first period.
  21. Consumption of alcohol and alcohol-containing foods and beverages less than 48 hours before taking the drug in the first period.
  22. Use of citrus fruits (including grapefruit and grapefruit juice) and cranberries (including juices, fruit drinks, etc.) less than 7 days before taking the drug in the first period.
  23. Intake of more than 10 units alcohol per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of dry wine or 50 ml of spirits) or history of alcoholism, drug addiction, drug abuse.
  24. Intense physical activity less than 24 hours before taking the drug in the first period.
  25. Smoking more than 10 cigarettes less than 24 hours before taking the drug in the first period.
  26. Participation in other clinical trials of drugs less than 3 months before taking the drug in the first period.
  27. Following any low sodium diet within 2 weeks prior to study initiation, or following a special diet (vegetarian, vegan, with limited salt intake) or lifestyle (night work, extreme physical activity).
  28. Test positive for syphilis, , or at the time of screening.
  29. Positive test for alcohol in exhaled air at screening.
  30. Positive urinalysis for the content of narcotic and potent substances during screening (opiates, morphine, barbiturates, benzodiazepines, cannabinoids/marijuana).
  31. The value of standard laboratory and instrumental parameters that go beyond the reference values.
  32. Lack of intention of volunteers to comply with the Protocol requirements throughout the course of the study and/or lack, in the opinion of the Investigator, of the volunteers' ability to understand and evaluate the information on this study as part of the form signing process, in particular regarding the expected risks and possible discomfort.
  33. Mental, physical and other reasons that do not allow the volunteer to adequately assess their behavior and correctly comply with the conditions of the research protocol.
  34. Tattooing and piercing within 30 days prior to first drug administration.
  35. Difficulty swallowing tablets.
  36. Difficulty with taking blood (for example, difficult access to the veins).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Other
    Sequence TR

    22 subjects assigned to the sequence TR will receive a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in Period 1 and a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Sildenafil film-coated tablet 100 mg · Drug: Viagra® film-coated tablet 100 mg

  • Other
    Sequence RT

    22 subjects assigned to the sequence RT will receive a single 100 mg dose of the reference product Viagra® (1 x 100 mg tablet), marked as R in the sequence, in Period 1 and a single 100 mg dose of the test product Sildenafil (1 x 100 mg tablet), marked as T in the sequence, in period 2. These treatments will be administered orally with approximately 200 mL of water, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.

    Drug: Sildenafil film-coated tablet 100 mg · Drug: Viagra® film-coated tablet 100 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Maximum observed concentration in plasma.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  2. AUC0-t of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference.

    Cumulative area under the concentration time curve calculated from 0 to time of last observed quantifiable concentration (TLQC) using the linear trapezoidal method

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

Secondary outcomes

  1. Tmax of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Time of maximum observed concentration; if it occurs at more than one time point, Tmax is defined as the first time point with this value.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  2. TLQC of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Time of last observed quantifiable concentration.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  3. AUC0-INF of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Area under the concentration time curve extrapolated to infinity, calculated as AUC0-t + ĈLQC (the predicted concentration at time TLQC) / λZ (apparent elimination rate constant).

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  4. Residual area of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Extrapolated area (i.e. percentage of AUC0-INF due to extrapolation from TLQC to infinity).

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  5. Time point where the log-linear elimination phase begins (TLIN) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference. products.

    Time point where the log-linear elimination phase begins.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  6. λZ of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Apparent elimination rate constant, estimated by linear regression of the terminal linear portion of the log concentration versus time curve.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  7. Terminal elimination half-life (Thalf) of sildenafil and N-Desmethyl Sildenafil in plasma after administration of the test and the reference products.

    Terminal elimination half-life, calculated as ln(2)/λZ.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

  8. Number of treatment-emergent adverse events for the test and the reference products.

    The safety population will include all subjects who received at least one dose of the test or the reference product. Any significant changes will be recorded as treatment-emergent adverse events only if they are judged clinically significant by the qualified investigator or delegate.

    Time frame: Time points 0.00 (prior to each drug administration) and 0.17, 0.33, 0.50, 0.67, 0.83, 1.00, 1.25, 1.50, 1.75, 2.00, 2.33, 2.67, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00 hours after each drug administration.

07

Study locations

1 site
  • Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl"
    Yaroslavl, 150047, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2021; primary completion for May 2021, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 12, 2021
StartEst.
May 10, 2021
Primary completionEst.
May 30, 2021
CompletionEst.
May 30, 2021
Last update
May 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04882826
Collaborators
ClinPharmInvest, LLC
Responsible party
Sponsor
First posted
May 12, 2021
Start date
May 10, 2021 (estimated)
Primary completion
May 30, 2021 (estimated)
Completion
May 30, 2021 (estimated)
Last update
May 12, 2021

Study contacts

Veronika Kumpel
Contact
specialist.fs@ft.by
80173094418
Andrei Yaremchuk
Contact
development@ft.by
Alexander Khokhlov
principal investigator · ClinPharmInvest, LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion